research use only

Baclofen GABA Receptor agonist

Name: Baclofen
Brand: Selleck Chemicals
SKU: S4840
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4840

Baclofen is a gamma-amino-butyric acid (GABA) derivative used as a skeletal muscle relaxant and central nervous system depressant. It activates GABA receptors, specifically the GABAB receptors.

Chemical Structure

Molecular Weight: 213.66

Jump to

Quality Control

Batch: S484001 0.01M HCl]3 mg/mL]true]Water]0.1 mg/mL]false]DMSO]Insoluble]false Purity: 99.79%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.79

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor TRP Channel Cholinesterase (ChE) GluR
Other GABA Receptor Inhibitors	Dihydromyricetin CGP52432 Ginkgolide A Pentylenetetrazol Oxiracetam 4-Aminobutyric acid (GABA) Emamectin Benzoate SR95531 Chinese Arborvilea Seed Extract Afoxolaner

Solubility

In vitro
Batch:

0.01M HCl : 3 mg/mL

Water : 0.1 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	213.66	Formula	C₁₀H₁₂ClNO₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1134-47-0	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1=CC(=CC=C1C(CC(=O)O)CN)Cl

Mechanism of Action

Targets/IC₅₀/Ki	GABAB receptor
In vitro	Baclofen induces G0/G1 phase arrest which is connected with down-regulation of intracellular cAMP level, and up-regulation of p21^WAF1 protein expression as well as its phosphorylation level in human hepatocellular carcinoma cell.
In vivo	Chronic treatment with baclofen markedly diminishes hippocampal atrophy and neuronal apoptosis in hippocampal CA1 area via the regulation of autophagy in chronic cerebral hypoperfusion in rats. This compound might suppress cytodestructive autophagic activity through Akt-GSK-3β-p-mTOR-Beclin 1 signaling pathway under chronic cerebral hypoperfusion. During brain ischemia, it could reduce CX43 and CX36 surface expression. Baclofen-induced suppression of increased CX43 and CX36 surface expressions helps neurons survive. This chemical reduces reinstatement to cocaine self-administration in an animal model of relapse. It suppresses Bel-7402 xenograft tumor growth in vivo.
References	[1] https://www.nature.com/articles/srep14474#discussion [2] https://pubmed.ncbi.nlm.nih.gov/12629530/ [3] https://pubmed.ncbi.nlm.nih.gov/18222491/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06175507	Not yet recruiting	Alcohol Liver Disease	Institute of Liver and Biliary Sciences India	December 25 2023	Not Applicable
NCT04603625	Active not recruiting	Quadriplegic Cerebral Palsy	Azienda Unità Sanitaria Locale Reggio Emilia\|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta\|Ospedale IRCCS G. Gaslini di Genova\|IRCCS Eugenio Medea\|IRCCS Don Carlo Gnocchi di Firenze\|Azienda Unita'' Sanitaria Locale Di Modena\|Azienda Usl di Bologna\|Azienda Unità Sanitaria Locale della Romagna\|Azienda ULSS di Verona e Provincia\|Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico	October 29 2020	Not Applicable
NCT04509336	Terminated	Cirrhosis	Mansoura University	August 20 2020	Not Applicable
NCT04471714	Withdrawn	Spasticity Muscle\|Spinal Cord Injuries	University of Alberta	January 10 2020	Phase 2
NCT03682978	Completed	Autism Spectrum Disorder	Celso Arango MD PhD\|UMC Utrecht	September 19 2019	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):